Literature DB >> 15345874

Newer drugs for asthma.

Meenu Singh1.   

Abstract

Several new drugs have resulted from innovative pharmacological and immunomodulatory approaches towards treatment of asthma. Diverse therapeutic targets have provided new agents. The new classes of drugs available are newer "on site activated inhaled corticisteroids" and soft steroids, anti IgE compounds, leukotriene inhibitors and single isomer agents which are available for clinical use. Anti interleukin agents and phosphodiesterase inhibitors are in the stage of clinical trials. Antisense therapy and pharmacogenetics are the on horizon for treatment of asthma.

Entities:  

Mesh：

Year:  2004        PMID： 15345874     DOI： 10.1007/bf02730663

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  19 in total

1.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

Review 2.  Soft drug design: general principles and recent applications.

Authors:  N Bodor; P Buchwald
Journal:  Med Res Rev       Date:  2000-01       Impact factor: 12.944

Review 3.  Treatment of asthma with drugs modifying the leukotriene pathway.

Authors:  J M Drazen; E Israel; P M O'Byrne
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

Review 4.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

Authors:  T J Torphy
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

5.  Characterization of the human cysteinyl leukotriene CysLT1 receptor.

Authors:  K R Lynch; G P O'Neill; Q Liu; D S Im; N Sawyer; K M Metters; N Coulombe; M Abramovitz; D J Figueroa; Z Zeng; B M Connolly; C Bai; C P Austin; A Chateauneuf; R Stocco; G M Greig; S Kargman; S B Hooks; E Hosfield; D L Williams; A W Ford-Hutchinson; C T Caskey; J F Evans
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

6.  Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

Authors:  A E Tattersfield; D S Postma; P J Barnes; K Svensson; C A Bauer; P M O'Byrne; C G Löfdahl; R A Pauwels; A Ullman
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

7.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

Authors:  D J Evans; D A Taylor; O Zetterstrom; K F Chung; B J O'Connor; P J Barnes
Journal:  N Engl J Med       Date:  1997-11-13       Impact factor: 91.245

8.  Cytokines in nasal fluids from school children with seasonal allergic rhinitis.

Authors:  M Benson; I L Strannegård; G Wennergren; O Strannegård
Journal:  Pediatr Allergy Immunol       Date:  1997-08       Impact factor: 6.377

9.  Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.

Authors:  H S Nelson; G Bensch; W W Pleskow; R DiSantostefano; S DeGraw; D S Reasner; T E Rollins; P D Rubin
Journal:  J Allergy Clin Immunol       Date:  1998-12       Impact factor: 10.793

Review 10.  Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.

Authors:  Jonathan Nyce
Journal:  Curr Opin Allergy Clin Immunol       Date:  2002-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.